Dr Danielle Bond

Dr Danielle Bond

Lecturer

School of Biomedical Sciences and Pharmacy

Career Summary

Biography

Dr Danielle Bond is an Early Career Researcher with the University of Newcastle’s School of Biomedical Sciences and Pharmacy. She is based at the Hunter Medical Research Institute (HMRI) and is associated with the Hunter Cancer Research Alliance (HCRA). Dr Bond’s research is focused on exploring the epigenetic changes that occur in cancer patients following drug treatment. This includes conducting groundwork research into the emerging role of tumour microenvironments on prognosis, treatment response and resistance. 

Dr Bond completed her PhD in medical biochemistry with the University of Newcastle in 2015. Her studies explored the post-transcriptional regulation of CD9 and CD151 by micro-RNAs in breast and prostate cancers. From 2015 to 2017, Dr Bond tested novel, natural and synthetic compounds, such as Vietnamese medicinal plants, as anti-pancreatic cancer agents. She was also involved in investigating blood markers for prostate cancer at the Ourimbah campus of the University of Newcastle.

In 2018, Dr Bond joined the Cancer Epigenetics group, led by Dr Heather Lee, as a postdoctoral scientist. Her role involved using cutting-edge single cell sequencing technology to test epigenetic processes such as DNA methylation and gene expression in Leukemia patients following treatment with cancer therapies. Dr Bond also undertook research to identify novel markers that could predict patient prognosis and response to current cancer treatments.

Dr Bond has presented her research at both national and international conferences and continues to publish her findings in high-impact journals. She has helped organise local scientific meetings and served as an RHD representative for the school research committee and deputy convenor of the Australian Society for Medical Research (ASMR) Newcastle committee.

Dr Bond has received pilot grant funding through the Faculty of Health and Medicine at the University of Newcastle and project funding from a CFMEU donor grant from HMRI. She is currently striving towards building an independent research program that aims to investigate epigenetic and transcriptional heterogeneity in cancer cells and their surrounding microenvironment in response to cancer therapy, with the help of a HMRI Leukemia Donor Grant received in late 2018.

Qualifications

  • Doctor of Philosophy, University of Newcastle
  • Bachelor of Biomedical Sciences, University of Newcastle
  • Bachelor of Biomedical Sciences (Hons), University of Newcastle

Keywords

  • Acute Myeloid Leukemia
  • Breast Cancer
  • DNA Methylation
  • Drug Discovery
  • Epigenetics
  • Gene Expression
  • Myelodsyplastic Syndrome
  • Pancreatic Cancer
  • Prostate Cancer
  • Tetraspanins
  • micro-RNA
  • multi-omics

Languages

  • English (Mother)

Fields of Research

Code Description Percentage
321103 Cancer genetics 100

Professional Experience

UON Appointment

Title Organisation / Department
Lecturer University of Newcastle
School of Biomedical Sciences and Pharmacy
Australia

Academic appointment

Dates Title Organisation / Department
14/4/2015 - 31/12/2017 Research Associate

Research Assistant

 Faculty of Science and Information Technology, The University of Newcastle | Australia
Environmental and Life Sciences
Australia

Awards

Prize

Year Award
2020 Highly commendable oral presentation
Hunter Cancer Research Alliance (HCRA)

Teaching

Code Course Role Duration
PHAR6704 Pharmacology of Chronic Conditions
School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle
Created course content on the management of cancer		 Content creator 11/1/2021 - 31/5/2021
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.

Journal article (19 outputs)

Year Citation Altmetrics Link
2023 Humphries S, Bond DR, Germon ZP, Keely S, Enjeti AK, Dun MD, Lee HJ, 'Crosstalk between DNA methylation and hypoxia in acute myeloid leukaemia', Clinical Epigenetics, 15 (2023) [C1]

Background: Acute myeloid leukaemia (AML) is a deadly disease characterised by the uncontrolled proliferation of immature myeloid cells within the bone marrow. Altered regulation ... [more]

Background: Acute myeloid leukaemia (AML) is a deadly disease characterised by the uncontrolled proliferation of immature myeloid cells within the bone marrow. Altered regulation of DNA methylation is an important epigenetic driver of AML, where the hypoxic bone marrow microenvironment can help facilitate leukaemogenesis. Thus, interactions between epigenetic regulation and hypoxia signalling will have important implications for AML development and treatment. Main body: This review summarises the importance of DNA methylation and the hypoxic bone marrow microenvironment in the development, progression, and treatment of AML. Here, we focus on the role hypoxia plays on signalling and the subsequent regulation of DNA methylation. Hypoxia is likely to influence DNA methylation through altered metabolic pathways, transcriptional control of epigenetic regulators, and direct effects on the enzymatic activity of epigenetic modifiers. DNA methylation may also prevent activation of hypoxia-responsive genes, demonstrating bidirectional crosstalk between epigenetic regulation and the hypoxic microenvironment. Finally, we consider the clinical implications of these interactions, suggesting that reduced cell cycling within the hypoxic bone marrow may decrease the efficacy of hypomethylating agents. Conclusion: Hypoxia is likely to influence AML progression through complex interactions with DNA methylation, where the therapeutic efficacy of hypomethylating agents may be limited within the hypoxic bone marrow. To achieve optimal outcomes for AML patients, future studies should therefore consider co-treatments that can promote cycling of AML cells within the bone marrow or encourage their dissociation from the bone marrow.

DOI 10.1186/s13148-023-01566-x
Co-authors Matt Dun, Heather Lee, Simon Keely, Anoop Enjeti
2022 Hunt K, Burnard SM, Roper EA, Bond DR, Dun MD, Verrills NM, et al., 'scTEM-seq: Single-cell analysis of transposable element methylation to link global epigenetic heterogeneity with transcriptional programs', SCIENTIFIC REPORTS, 12 (2022) [C1]
DOI 10.1038/s41598-022-09765-x
Citations Scopus - 7Web of Science - 3
Co-authors Sean Burnard, Matt Dun, Heather Lee, Nikki Verrills, Anoop Enjeti
2020 Turner A, Bond DR, Vuong QV, Chalmers A, Beckett EL, Weidenhofer J, Scarlett CJ, 'Elaeocarpus reticulatus fruit extracts reduce viability and induce apoptosis in pancreatic cancer cells in vitro', Molecular Biology Reports, 47 2073-2084 (2020) [C1]
DOI 10.1007/s11033-020-05307-8
Citations Scopus - 5Web of Science - 3
Co-authors C Scarlett, Judith Weidenhofer, Vanquan Vuong, Anita Chalmers, Emma Beckett
2020 Bond DR, Uddipto K, Enjeti AK, Lee HJ, 'Single-cell epigenomics in cancer: Charting a course to clinical impact', Epigenomics, 12 1139-1151 (2020) [C1]

Cancer is a disease of global epigenetic dysregulation. Mutations in epigenetic regulators are common events in multiple cancer types and epigenetic therapies are emerging as a tr... [more]

Cancer is a disease of global epigenetic dysregulation. Mutations in epigenetic regulators are common events in multiple cancer types and epigenetic therapies are emerging as a treatment option in several malignancies. A major challenge for the clinical management of cancer is the heterogeneous nature of this disease. Cancers are composed of numerous cell types and evolve over time. This heterogeneity confounds decisions regarding treatment and promotes disease relapse. The emergence of single-cell epigenomic technologies has introduced the exciting possibility of linking genetic and transcriptional heterogeneity in the context of cancer biology. The next challenge is to leverage these tools for improved patient outcomes. Here we consider how single-cell epigenomic technologies may address the current challenges faced by cancer clinicians.

DOI 10.2217/epi-2020-0046
Citations Scopus - 8Web of Science - 6
Co-authors Anoop Enjeti, Heather Lee
2020 Bond DR, Kahl R, Brzozowski JS, Jankowski H, Naudin C, Pariyar M, et al., 'Tetraspanin CD9 is regulated by MiR-518f-5p and functions in breast cell migration and in vivo tumor growth', Cancers, 12 (2020) [C1]
DOI 10.3390/cancers12040795
Citations Scopus - 11Web of Science - 10
Co-authors Murray Cairns, Severine Roselli, C Scarlett, Judith Weidenhofer, Kelly Kiejda, Leonie Ashman
2020 Bond DR, Lee HJ, Enjeti AK, 'Unravelling the epigenome of myelodysplastic syndrome: Diagnosis, prognosis, and response to therapy', Cancers, 12 1-25 (2020) [C1]
DOI 10.3390/cancers12113128
Citations Scopus - 10Web of Science - 7
Co-authors Anoop Enjeti, Heather Lee
2019 Predebon MJ, Bond DR, Brzozowski J, Jankowski H, Deane F, Tarleton M, et al., 'The bispidinone derivative 3,7-Bis-[2-(S)-amino-3-(1H-indol-3-yl)-propionyl]-1,5-diphenyl-3,7-diazabicyclo[3.3.1]nonan-9-one dihydrochloride induces an apoptosis-mediated cytotoxic effect on pancreatic cancer cells in vitro', Molecules, 24 (2019) [C1]
DOI 10.3390/molecules24030524
Citations Scopus - 4Web of Science - 3
Co-authors Adam Mccluskey, Michael Bowyer, Judith Weidenhofer, C Scarlett
2018 Brzozowski JS, Jankowski H, Bond DR, McCague SB, Munro BR, Predebon MJ, et al., 'Lipidomic profiling of extracellular vesicles derived from prostate and prostate cancer cell lines.', Lipids Health Dis, 17 211 (2018) [C1]
DOI 10.1186/s12944-018-0854-x
Citations Scopus - 97Web of Science - 79
Co-authors Judith Weidenhofer, C Scarlett, Kathryn Skelding
2018 Brzozowski JS, Bond DR, Jankowski H, Goldie BJ, Burchell R, Naudin C, et al., 'Extracellular vesicles with altered tetraspanin CD9 and CD151 levels confer increased prostate cell motility and invasion', Scientific Reports, 8 1-13 (2018) [C1]
DOI 10.1038/s41598-018-27180-z
Citations Scopus - 49Web of Science - 37
Co-authors Kathryn Skelding, Matt Dun, C Scarlett, Judith Weidenhofer
2018 Bond DR, Naudin C, Carroll AP, Goldie BJ, Brzozowski JS, Jankowski HM, et al., 'miR-518f-5p decreases tetraspanin CD9 protein levels and differentially affects non-tumourigenic prostate and prostate cancer cell migration and adhesion', ONCOTARGET, 9 1980-1991 (2018) [C1]
DOI 10.18632/oncotarget.23118
Citations Scopus - 9Web of Science - 7
Co-authors Leonie Ashman, Judith Weidenhofer, C Scarlett, Murray Cairns
2018 Goldsmith CD, Bond D, Jankowski H, Weidenhofer JC, Stathopoulos C, Roach PD, Scarlett CJ, 'The Olive Biophenols Oleuropein and Hydroxytyrosol Selectively Reduce Proliferation, Influence the Cell Cycle, and Induce Apoptosis in Pancreatic Cancer Cells', International Journal of Molecular Sciences, 19 (2018) [C1]
DOI 10.3390/ijms19071937
Citations Scopus - 80Web of Science - 62
Co-authors Judith Weidenhofer, C Scarlett
2018 Hong NTP, Sakoff JA, Bond DR, Quan VV, Bowyer MC, Scarlett CJ, 'In vitro antibacterial and anticancer properties of Helicteres hirsuta Lour. leaf and stem extracts and their fractions', MOLECULAR BIOLOGY REPORTS, 45 2125-2133 (2018) [C1]
DOI 10.1007/s11033-018-4370-x
Citations Scopus - 13Web of Science - 12
Co-authors Vanquan Vuong, C Scarlett, Michael Bowyer
2018 Bhuyan DJ, Vuong QV, Bond DR, Chalmers AC, Bowyer MC, Scarlett CJ, 'Eucalyptus microcorys leaf extract derived HPLC-fraction reduces the viability of MIA PaCa-2 cells by inducing apoptosis and arresting cell cycle', Biomedicine and Pharmacotherapy, 105 449-460 (2018) [C1]
DOI 10.1016/j.biopha.2018.05.150
Citations Scopus - 16Web of Science - 10
Co-authors Anita Chalmers, Michael Bowyer, Vanquan Vuong, C Scarlett
2017 Bhuyan DJ, Sakoff J, Bond DR, Predebon M, Vuong QV, Chalmers AC, et al., 'In vitro anticancer properties of selected Eucalyptus species', IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, 53 604-615 (2017) [C1]
DOI 10.1007/s11626-017-0149-y
Citations Scopus - 20Web of Science - 18
Co-authors Vanquan Vuong, Michael Bowyer, Anita Chalmers, Ian Vanaltena, C Scarlett
2017 Bhuyan DJ, Vuong QV, Bond DR, Chalmers AC, van Altena IA, Bowyer MC, Scarlett CJ, 'Exploring the Least Studied Australian Eucalypt Genera: Corymbia and Angophora for Phytochemicals with Anticancer Activity against Pancreatic Malignancies', CHEMISTRY & BIODIVERSITY, 14 (2017) [C1]
DOI 10.1002/cbdv.201600291
Citations Scopus - 11Web of Science - 7
Co-authors Vanquan Vuong, Ian Vanaltena, Michael Bowyer, C Scarlett, Anita Chalmers
2017 Naudin C, Smith B, Bond DR, Dun MD, Scott RJ, Ashman LK, et al., 'Characterization of the early molecular changes in the glomeruli of Cd151 -/- mice highlights induction of mindin and MMP-10.', Scientific Reports, 7 15987-15987 (2017) [C1]
DOI 10.1038/s41598-017-15993-3
Citations Scopus - 11Web of Science - 9
Co-authors Matt Dun, Leonie Ashman, Rodney Scott, Severine Roselli, Judith Weidenhofer
2016 Weidenhofer JC, Colvin EK, Bond DR, Scarlett CJ, 'Animal models of pancreatic cancer and their application in clinical research', Gastrointestinal Cancer : Targets and Therapy, 2016 31-39 (2016) [C1]
Co-authors Judith Weidenhofer, C Scarlett
2014 Pundavela J, Demont Y, Jobling P, Lincz LF, Roselli S, Thorne RF, et al., 'ProNGF correlates with Gleason score and is a potential driver of nerve infiltration in prostate cancer', American Journal of Pathology, 184 3156-3162 (2014) [C1]

Nerve infiltration is essential to prostate cancer progression, but the mechanism by which nerves are attracted to prostate tumors remains unknown. We report that the precursor of... [more]

Nerve infiltration is essential to prostate cancer progression, but the mechanism by which nerves are attracted to prostate tumors remains unknown. We report that the precursor of nerve growth factor (proNGF) is overexpressed in prostate cancer and involved in the ability of prostate cancer cells to induce axonogenesis. A series of 120 prostate cancer and benign prostate hyperplasia (BPH) samples were analyzed by IHC for proNGF. ProNGF was mainly localized in the cytoplasm of epithelial cells, with marked expression in cancer compared with BPH. Importantly, the proNGF level positively correlated with the Gleason score (n = 104, tB = 0.51). A higher level of proNGF was observed in tumors with a Gleason score of =8 compared with a Gleason score of 7 and 6 (P < 0.001). In vitro, proNGF was detected in LNCaP, DU145, and PC-3 prostate cancer cells and BPH-1 cells but not in RWPE-1 immortalized nontumorigenic prostate epithelial cells or primary normal prostate epithelial cells. Co-culture of PC12 neuronal-like cells or 50B11 neurons with PC-3 cells resulted in neurite outgrowth in neuronal cells that was inhibited by blocking antibodies against proNGF, indicating that prostate cancer cells can induce axonogenesis via secretion of proNGF. These data reveal that ProNGF is a biomarker associated with high-risk prostate cancers and a potential driver of infiltration by nerves.

DOI 10.1016/j.ajpath.2014.08.009
Citations Scopus - 83Web of Science - 67
Co-authors Hubert Hondermarck, Severine Roselli, Lisa Lincz, Phillip Jobling, Marjorie Walker
2014 Bond DB, Brzozowski J, Skelding KA, Roselli SR, Weidenhofer J, 'Use of tetraspanins CD151 and CD9 as biomarkers for breast cancer', Breast Cancer Management, 3 123-126 (2014) [C3]
DOI 10.2217/bmt.14.2
Co-authors Kathryn Skelding, Judith Weidenhofer, Severine Roselli
Show 16 more journal articles

Conference (18 outputs)

Year Citation Altmetrics Link
2020 Bond DR, Lee HJ, Enjeti AK, 'Poster Presentation Abstracts', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2020)
DOI 10.1111/ajco.13473
Co-authors Billie Bonevski, Heather Lee, Anoop Enjeti
2019 Jankowski H, Munro B, McCague S, Quick G, Brzozowski J, Bond D, et al., 'Vault RNAs Have a Functional Role in Prostate Cancer', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2019)
Co-authors Judith Weidenhofer, Kathryn Skelding, C Scarlett
2017 Bond D, Phuong TT, Do TH, Nguyen MK, Weidenhofer J, Scarlett CJ, 'Vietnamese medicinal plant compounds show potent anti-pancreatic cancer activity in vitro', CANCER RESEARCH, Washington, DC (2017)
DOI 10.1158/1538-7445.AM2017-2175
Co-authors Judith Weidenhofer, C Scarlett
2017 Goldsmith CD, Jankowski H, Bond D, Weidenhofer J, Stathopoulos C, Roach P, Scarlett C, 'The olive biophenol oleuropein selectively induces apoptosis in pancreatic cancer cells in vitro', CANCER RESEARCH, Washington, DC (2017)
DOI 10.1158/1538-7445.AM2017-2177
Co-authors Judith Weidenhofer, C Scarlett
2016 Goldsmith C, Bond D, Stathopoulos C, Roach P, Scarlett C, 'THE OLIVE PHENOLIC COMPOUNDS APIGENIN, LUTEOLIN AND OLEUROPEIN INDUCE CELL-CYCLE ARREST AND APOPTOSIS IN PANCREATIC CANCER CELLS IN VITRO', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2016)
Co-authors C Scarlett
2016 Jankowski H, Brzozowski J, Goldie B, Bond D, Munro B, Scarlett C, et al., 'PROSTATE CANCER EXTRACELLULAR VESICLES: FRIEND OR FOE', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2016)
Co-authors Judith Weidenhofer, C Scarlett, Kathryn Skelding
2016 Bond D, Thuong PT, Thiha D, Khoi NM, Cuong NM, Weidenhofer J, Scarlett C, 'PURE COMPOUNDS FROM VIETNAMESE MEDICINAL PLANTS SHOW PROMISING ANTI-PANCREATIC CANCER ACTIVITY IN VITRO', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2016)
Co-authors C Scarlett, Judith Weidenhofer
2016 Brzozowski J, Jankowski H, Munro B, Predebon M, Bond D, Scarlett C, et al., 'ALTERATIONS IN LIPID COMPOSITION OF NORMAL AND TUMOR-DERIVED PROSTATE EXTRACELLULAR VESICLES', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2016)
Co-authors Judith Weidenhofer, C Scarlett, Kathryn Skelding
2016 Jankowski H, Goldie B, Brzozowski J, Munro B, Bond D, Scarlett C, et al., 'TETRASPANIN CD9 MODIFIES EXTRACELLULAR VESICLE NUCLEIC ACID CARGO IN PROSTATE CELL LINES', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2016)
Co-authors C Scarlett, Judith Weidenhofer, Kathryn Skelding
2015 Jankowski H, Goldie B, Brzozowski J, Bond D, Scarlett C, Skelding KA, Weidenhofer J, 'Differences in extracellular vesicle nucleic acid content show promise as prostate cancer biomarkers', Boston, MA (2015) [O1]
Co-authors Judith Weidenhofer, Kathryn Skelding, C Scarlett
2015 Brzozowski J, Coldie B, Jankowski H, Bond D, Scarlett C, Dun M, et al., 'THE EFFECTS OF ALTERED CD9 AND CD151 EXPRESSION ON PROSTATE EXOSOMES', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors C Scarlett, Kathryn Skelding, Judith Weidenhofer, Matt Dun
2015 Jankowski H, Goldie B, Brzozowski J, Bond D, Scarlett C, Skelding K, Weidenhofer J, 'PROSTATE CANCER BIOMARKERS: ARE EXTRACELLULAR VESICLES THE SOLUTION?', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Kathryn Skelding, Judith Weidenhofer, C Scarlett
2015 Bond D, Turner A, Richmond R, Sadeqzadeh E, Vuong Q, Bhuyan D, et al., 'THE SEARCH FOR NOVEL TREATMENT AGENTS FOR PANCREATIC CANCER: TALES FROM THE LAND AND SEA', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Judith Weidenhofer, Vanquan Vuong, C Scarlett, Michael Bowyer, Troy Gaston, Anita Chalmers, Ian Vanaltena
2015 Predebon M, Bond D, Brzozowski J, Jankowski H, Deane F, Tarleton M, et al., 'A BISPIDINONE ANALOGUE INDUCES AN APOPTOSIS-MEDIATED CYTOTOXIC EFFECT ON PANCREATIC CANCER CELLS IN VITRO', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors C Scarlett, Michael Bowyer, Adam Mccluskey, Judith Weidenhofer
2014 Bond DR, Passfield C, Cairns M, Ashman LK, Weidenhofer J, 'Posttranscriptional regulation of tetraspanins CD151 & CD9 in breast & prostate cancers', CANCER RESEARCH, San Diego, CA (2014) [E3]
DOI 10.1158/1538-7445.AM2014-4364
Co-authors Judith Weidenhofer, Leonie Ashman, Murray Cairns
2013 Weidenhofer J, Bond D, Copeland B, Ashman L, 'Tetraspanin protein turnover rates vary in prostate cancer cell lines', BJU INTERNATIONAL (2013) [E3]
Co-authors Judith Weidenhofer, Leonie Ashman
2013 Bond D, Cairns M, Ashman L, Weidenhofer J, 'Post-transcriptional regulation of CD151 & CD9 by miRNAs in prostate cancer', BJU INTERNATIONAL (2013) [E3]
Co-authors Murray Cairns, Judith Weidenhofer, Leonie Ashman
2012 Bond DR, Cairns MJ, Ashman LK, Weidenhofer JC, 'Investigating micro-RNA regulation of tetraspanins CD151 and CD9 in prostate cancer', Febs Journal, Seville, Spain (2012) [E3]
Co-authors Leonie Ashman, Judith Weidenhofer, Murray Cairns
Show 15 more conferences

Preprint (4 outputs)

Year Citation Altmetrics Link
2024 Bond DR, Burnard SM, Uddipto K, Hunt KV, Harvey BM, Reinhardt LS, et al., 'Upregulated cholesterol biosynthesis facilitates the survival of methylation-retaining AML cells following decitabine treatment (2024)
DOI 10.1101/2024.01.30.577864
Co-authors Heather Murray, Nikola Bowden, Sean Burnard, Carlos Riveros, Anoop Enjeti, Heather Lee, Nikki Verrills, Luiza Steffens
2023 Humphries S, Burnard S, Keely S, Bond D, Lee H, 'Hypoxia alters the effects of hypomethylating agents in acute myeloid leukaemia cells (2023)
DOI 10.1101/2023.12.07.570313
Co-authors Heather Lee, Sean Burnard, Simon Keely
2022 Hunt K, Burnard S, Bond D, Lee H, 'Protocol for targeted analysis of transposable element methylation levels and transcriptome in single cells using scTEM-seq (2022)
DOI 10.21203/rs.3.pex-2075/v1
Co-authors Heather Lee, Sean Burnard
2021 Hunt K, Burnard S, Roper E, Bond D, Dun M, Verrills N, et al., 'SINEultaneous profiling of epigenetic heterogeneity and transcriptome in single cells (2021)
DOI 10.1101/2021.03.25.436351
Co-authors Matt Dun, Sean Burnard, Anoop Enjeti, Heather Lee, Nikki Verrills
Show 1 more preprint
Edit

Grants and Funding

Summary

Number of grants 8
Total funding $1,488,818

Click on a grant title below to expand the full details for that specific grant.

20241 grants / $827,655

Mesenchymal Signal Targeting in Myelodysplasia as a pathway to transfusion independence and blood count improvement – the MESSAGE study$827,655

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Doctor Anoop Enjeti, Doctor Danielle Bond, Dr Belinda Butcher, Dr Robin Gasiorowsko, Dr Devendra Hiwase, Associate Professor Zoe McQuilten, Doctor Heather Murray, Prof Andrew Wei, Dr Chun Yew Fong
Scheme MRFF - Early to Mid-Career Researchers Grant
Role Investigator
Funding Start 2024
Funding Finish 2027
GNo G2300838
Type Of Funding C1300 - Aust Competitive - Medical Research Future Fund
Category 1300
UON Y

20233 grants / $167,996

Targeting cholesterol biosynthesis for improved efficacy of hypomethylating agents in acute myeloid leukaemia$100,000

Funding body: Cure Cancer Australia Foundation

Funding body Cure Cancer Australia Foundation
Project Team Doctor Danielle Bond, Professor Matt Dun, Doctor Anoop Enjeti, Doctor Heather Lee, Associate Professor Nikki Verrills
Scheme Research Grant
Role Lead
Funding Start 2023
Funding Finish 2023
GNo G2200647
Type Of Funding C1700 - Aust Competitive - Other
Category 1700
UON Y

Targeting cholesterol biosynthesis for improved efficacy of hypomethylating agents in acute myeloid leukaemia$63,000

Funding body: NSW Health Pathology - Pathology North

Funding body NSW Health Pathology - Pathology North
Project Team Doctor Danielle Bond, Doctor Anoop Enjeti
Scheme Research Grant
Role Lead
Funding Start 2023
Funding Finish 2024
GNo G2300884
Type Of Funding C2300 – Aust StateTerritoryLocal – Own Purpose
Category 2300
UON Y

Assessing a new epigenetic therapy in AML$4,996

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Doctor Danielle Bond
Scheme Pilot Funding Scheme
Role Lead
Funding Start 2023
Funding Finish 2023
GNo G2300481
Type Of Funding Internal
Category INTE
UON Y

20211 grants / $68,167

HMRI Researcher Bridging Fund$68,167

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Danielle Bond
Scheme Research Grant
Role Lead
Funding Start 2021
Funding Finish 2021
GNo G2100222
Type Of Funding C3300 – Aust Philanthropy
Category 3300
UON Y

20181 grants / $20,000

Investigating the role of stromal heterogeneity in Myelodysplastic Syndrome following Azacitadine therapy $20,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Danielle Bond, Doctor Heather Lee, Doctor Anoop Enjeti
Scheme Project Grant
Role Lead
Funding Start 2018
Funding Finish 2018
GNo G1801353
Type Of Funding C3300 – Aust Philanthropy
Category 3300
UON Y

20141 grants / $400,000

Tetraspanin CD9; more than just an exosome marker - A novel biomarker to target for prostate cancer$400,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Jude Weidenhofer, Associate Professor Kathryn Skelding, Professor Matt Dun, Ms Belinda Goldie, Doctor Danielle Bond
Scheme Project Grant
Role Investigator
Funding Start 2014
Funding Finish 2017
GNo G1400921
Type Of Funding C3300 – Aust Philanthropy
Category 3300
UON Y

20111 grants / $5,000

Investigation of miRNA targeting of tetraspanins CD151 and CD9 in breast cancer $5,000

Funding body: The Faculty of Health, The University of Newcastle

Funding body The Faculty of Health, The University of Newcastle
Project Team

Judith Weidenhofer, Murray Cairns & Danielle Bond
Scheme Faculty of Health Pilot Grant
Role Investigator
Funding Start 2011
Funding Finish 2011
GNo
Type Of Funding Internal
Category INTE
UON N
Edit

Research Supervision

Number of supervisions

Completed2
Current2

Current Supervision

Commenced Level of Study Research Title Program Supervisor Type
2023 PhD Clinical Implications of Treatment-Induced Epigenetic Heterogeneity in Acute Myeloid Leukaemia PhD (Medical Genetics), College of Health, Medicine and Wellbeing, The University of Newcastle Co-Supervisor
2020 PhD Investigating the Effect of Hypoxia on Hypomethylating Agent Efficacy and Downstream Transcriptional Implications in Acute Myeloid Leukaemia PhD (Medical Genetics), College of Health, Medicine and Wellbeing, The University of Newcastle Co-Supervisor

Past Supervision

Year Level of Study Research Title Program Supervisor Type
2023 PhD The Link Between Aberrations in the p53 Pathway and Outcomes from DNA-Damaging Therapies in Breast Cancer PhD (Medical Genetics), College of Health, Medicine and Wellbeing, The University of Newcastle Co-Supervisor
2022 PhD Single Cell Epigenomics in Myeloid Malignancies PhD (Medical Genetics), College of Health, Medicine and Wellbeing, The University of Newcastle Co-Supervisor
Edit

News

Blood researcher Dr Heather Murray

News • 3 Feb 2023

Early-career researchers boosted in mission to beat cancer

On the eve of World Cancer Day on 4 February, four University of Newcastle early career cancer researchers have been awarded $360,000 in grants to support their work investigating blood, gynaecological and colorectal cancers.

Dr Danielle Bond

Position

Lecturer
Cancer Epigenetics
School of Biomedical Sciences and Pharmacy
College of Health, Medicine and Wellbeing

Contact Details

Email danielle.bond@newcastle.edu.au
Phone 40420872

Office

Room Level 3 West
Building HMRI
Location HMRI

,
Edit

Research Networks